Abortion Case Could Harm Womens' Health and Upset Pharma Markets
- Bias Rating
-18% Somewhat Liberal
- Reliability
60% ReliableFair
- Policy Leaning
-18% Somewhat Liberal
- Politician Portrayal
6% Negative
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
40% Positive
- Liberal
- Conservative
Sentence | Sentiment | Bias |
---|---|---|
Unlock this feature by upgrading to the Pro plan. |
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
61% : Access to telehealth -- which the Fifth Circuit's order would limit -- is especially important to patients who don't live close to abortion services, including those who live in states where abortion remains illegal, and who rely on prescriptions sent by providers in states with abortion shield laws.56% : v. United States Food & Drug Admin., 5th Cir., 23-10362, 8/16/23.
52% : A ruling for the challenges may further the high court's project of dismantling the administrative state.
51% : In 2016, after reviewing overwhelming evidence of mifepristone's efficacy and safety, the FDA removed the requirement for follow-up appointments, permitted the drug's use in pregnancies up to 10 weeks in duration, and allowed non-physician clinicians to prescribe it.
50% : Although the original approval of mifepristone and application of the Comstock Act aren't now before the Supreme Court, a decision affirming the Fifth Circuit's ruling will have enormous ramifications for reproductive health.
49% : This article does not necessarily reflect the opinion of Bloomberg Industry Group, Inc., the publisher of Bloomberg Law and Bloomberg Tax, or its owners.
44% : Explaining why the courts shouldn't upset the restrictions on mifepristone that were then in place, Chief Justice John Roberts wrote that "courts owe significant deference to the politically accountable entities with the 'background, competence, and expertise to assess public health."In the three years since, the court's majority has repeatedly rejected his advice, denying deference to the expert decisions of the Centers for Disease Control and Prevention, the Occupational Safety and Health Administration, and the Environmental Protection Agency.
43% : He also found the FDA's actions were likely arbitrary and capricious in violation of the Administrative Procedure Act and the Comstock Act, a 19th-century law that prohibits distribution via mail of drugs and instruments used to support abortions.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.